Orchestra BioMed Holdings, Inc.
OBIO
$4.49
-$0.08-1.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,169.22% | 6.46% | 41.61% | 30.23% | -4.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,169.22% | 6.46% | 41.61% | 30.23% | -4.42% |
| Cost of Revenue | -6.86% | 2.07% | 30.12% | 21.59% | 9.68% |
| Gross Profit | 1,267.79% | 6.81% | 42.60% | 30.98% | -5.44% |
| SG&A Expenses | 12.47% | 14.90% | 5.25% | 11.74% | 18.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.41% | 24.39% | 22.94% | 26.65% | 23.35% |
| Operating Income | 19.43% | -25.18% | -22.27% | -26.51% | -24.84% |
| Income Before Tax | 13.64% | -30.19% | -25.41% | -28.41% | -24.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.64% | -30.19% | -25.41% | -28.41% | -24.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.64% | -30.19% | -25.41% | -28.41% | -24.23% |
| EBIT | 19.43% | -25.18% | -22.27% | -26.51% | -24.84% |
| EBITDA | 19.55% | -25.25% | -22.32% | -26.60% | -24.94% |
| EPS Basic | 21.72% | -13.82% | -16.86% | -20.75% | -11.48% |
| Normalized Basic EPS | 21.88% | -16.97% | -19.53% | -23.68% | -13.92% |
| EPS Diluted | 21.72% | -13.82% | -16.86% | -20.75% | -11.48% |
| Normalized Diluted EPS | 21.88% | -16.97% | -19.53% | -23.68% | -13.92% |
| Average Basic Shares Outstanding | 29.55% | 15.61% | 7.29% | 6.35% | 11.02% |
| Average Diluted Shares Outstanding | 29.55% | 15.61% | 7.29% | 6.35% | 11.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |